View Clinical Trial (Medical Research Study)

A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials

---

Conditions:		Alzheimer's Disease
Purpose:		This study is designed as a single ascending dose study in healthy subjects to evaluate safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) in plasma and Cerebrospinal (CSF) following single oral doses of E2212.
Study Summary:
Criteria:		Inclusion Criteria: 1. Healthy men and women of non-child bearing potential age 18 and 55 years old at the time of Screening; 2. Body mass index (BMI) 18 and 30 kg/m2 at Screening; 3. Are willing and able to comply with all aspects of the protocol; and 4. Provide written informed consent. Exclusion Criteria: 1. Clinically important abnormalities on physical examination, vital signs or clinical laboratories. 2. History of serious medical illness 3. Smoking or use of tobacco-containing products within past 3 months 4. History of alcohol or drug abuse within past 2 years
NCT ID:		NCT01221259
Primary Contact:		Principal Investigator Philip Lee, Md Quintiles Phase One Service
Backup Contact:		N/A
Location Contact:		Overland Park, Kansas United States There is no listed contact information for this specific location. Site Status: N/A

---

---